Sandra Hanner


IDO Inhibitor/Chemo Combo Shows Early Promise in Advanced Pancreatic Cancer

April 27th 2016

Nathan Bahary, MD, discusses results of a study that showed that the combination of indoximod with standard chemotherapy yielded a response rate of 42% as a first-line therapy for patients with metastatic pancreatic adenocarcinoma.

Palbociclib Showed Antiproliferative Activity in Early-stage Breast Cancer

April 18th 2016

Palbociclib may have antiproliferative effects when used as a neoadjuvant therapy for women with early stage breast cancer.

MAGE-A3—Targeted Adoptive T-Cell Therapy Shows Promise in Solid Tumors

April 17th 2016

A form of immunotherapy that harnesses the power of CD4 T-cells was shown to be safe and effective in patients with various types of metastatic cancers.

Ensituximab Shows Promise in Refractory mCRC

April 8th 2016

Treatment with ensituximab (NPC-1C), a chimeric IgG1 monoclonal antibody, induced stable disease in nearly half of patients with chemotherapy-refractory metastatic colorectal cancer without contributing significant toxicity.

Pancreatic Cancer Survival Rates Lower in Real World Than Clinical Trials

April 8th 2016

Patients with pancreatic adenocarcinoma enrolled on clinical trials have “profoundly improved survival” compared with patients in the general population, suggesting that oncologists who use trial data to prognosticate may be missing the mark.

Personalized Medicine Plausible in Pancreatic Cancer

April 7th 2016

Genomic and proteomic characterization of pancreatic cancer tumors can effectively be used to prescreen patients for clinical trials exploring molecularly matched targeted therapies.

Zoledronic Acid Does Not Add to Upfront Docetaxel Survival Benefit in Advanced Prostate Cancer

October 5th 2015

An updated analysis of the STAMPEDE trial upholds the survival benefit observed with early use of docetaxel in advanced prostate cancer, but does not support the introduction of zoledronic acid.

2015 NCCN Guideline Updates: New Recommendations for Clinical Practice

July 12th 2015

Expert panel members highlight the latest NCCN guideline recommendations.

Lanreotide Effective in Pancreatic NET Subgroup

January 17th 2015

Lanreotide improved progression-free survival and resulted in more disease control compared with an observation strategy among patients with pancreatic neuroendocrine tumors.

Expanded NAPOLI-1 Analysis Further Characterizes MM-398 Benefit in Metastatic Pancreatic Cancer

January 17th 2015

Expanded analysis of the NAPOLI-1 trial's per-protocol population continues to support the benefit of adding the nanoliposomal encapsulation of irinotecan MM-398 to 5-fluorouracil plus leucovorin for the treatment of patients with metastatic pancreatic cancer who were previously treated with gemcitabine.

Updated KEYNOTE-012 Shows Activity for Pembrolizumab in Gastric Cancer

January 15th 2015

Among patients with metastatic gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab, the agent showed promising antitumor activity and a manageable toxicity profile.

Adding Trastuzumab to Fulvestrant Prolongs Responses in Metastatic Breast Cancer

September 7th 2014

The addition of trastuzumab to fulvestrant prolonged responses compared with fulvestrant alone for certain patients with metastatic breast cancer.

Novel Clinical Trial "Graduates" Two Promising Agents

March 18th 2014

The first results from the I-SPY 2 trial, which is evaluating novel agents in the neoadjuvant treatment of breast cancer, show encouraging possibilities for veliparib (ABT-888) and neratinib (PB272).

RAS Mutational Analyses in mCRC Trials Highlight Need to 'Think Beyond KRAS'

January 20th 2014

Studies presented at the 2014 GI Cancers Symposium emphasized the need for full RAS mutational analyses in the management of metastatic colorectal cancer prior to initiating treatment with anti-EGFR monoclonal antibodies.

Novel Trial Design Shows Early Value for Veliparib/Carboplatin in TNBC

December 13th 2013

The first results from the novel the I-SPY 2 trial show encouraging possibilities for a veliparib/carboplatin combination therapy in TNBC.

Carboplatin Improves pCR More Than Bevacizumab in TNBC

December 13th 2013

The addition of carboplatin to standard neoadjuvant chemotherapy increased pathologic complete response rates in patients with triple-negative breast cancer.

Benefits of Screening Mammography Not So Inconsistent, After All

December 12th 2013

The benefit of screening mammography is more consistent across studies than has previously been thought, according to an analysis of key screening studies presented at the 2013 San Antonio Breast Cancer Symposium.

Dual HER2 Blockade Less Effective in PI3KCA-Mutant Breast Cancer

October 1st 2013

Breast cancer patients with PI3KCA mutations are less likely to achieve a pathological complete response from dual HER2 blockade in the neoadjuvant setting.

Survival Benefit Observed With Cetuximab in RAS Wild-Type Colorectal Cancer

September 30th 2013

Cetuximab plus FOLFIRI may offer a survival advantage over FOLFIRI plus bevacizumab in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer who do not have RAS mutations.

OS Comparable for Panitumumab and Cetuximab in KRAS Wild-Type mCRC

September 29th 2013

Panitumumab proved noninferior to cetuximab in extending overall survival in patients with chemorefractory KRAS wild-type metastatic colorectal cancer.